We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+10.82%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$113M
AUM Growth
+$10.6M
Cap. Flow
+$24.6M
Cap. Flow %
21.81%
Top 10 Hldgs %
74.15%
Holding
28
New
6
Increased
4
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$11.8M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.7M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$6.58M
4
TSRO
TESARO, Inc.
TSRO
+$3.34M
5
ONC
BeOne Medicines Ltd
ONC
+$2.25M

Top Sells

Rank Stock Value
1
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$9.21M
2
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$2.09M
3
ZGNX
Zogenix, Inc.
ZGNX
+$1.55M
4
SPHS
Sophiris Bio, Inc.
SPHS
+$786K
5
ACHV icon
Achieve Life Sciences
ACHV
+$60K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
1
BeOne Medicines Ltd
ONC
$32.8B
$14.7M 13.04%
493,630
+76,751
+18% +$2.25M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$14.3M 12.66%
705,159
– –
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
$9.4M 8.33%
232,600
-1,000
-0.4% -$38K
INCY icon
4
Incyte
INCY
$24.2B
$8M 7.09%
100,000
– –
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$6.99M 6.19%
+20,000
New +$7.7M
ACHC icon
6
Acadia Healthcare
ACHC
$2.76B
$6.52M 5.78%
+200,938
New +$11.8M
TSRO
7
DELISTED
TESARO, Inc.
TSRO
$6.3M 5.59%
+75,000
New +$3.34M
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$6.17M 5.47%
+450,000
New +$6.58M
NGNE icon
9
Neurogene
NGNE
$656M
$5.81M 5.15%
43,888
+2,887
+7% +$459K
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.6B
$5.45M 4.83%
70,000
– –
AVXS
11
DELISTED
AveXis, Inc. Common Stock
AVXS
$5.42M 4.81%
142,664
+59,388
+71% +$2.01M
ARDM
12
DELISTED
Aradigm Corp Common Stock
ARDM
$4.81M 4.27%
1,101,513
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.14M 3.67%
757,935
– –
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.69B
$2.31M 2.05%
234,220
– –
AKTX
15
Akari Therapeutics
AKTX
$13.8M
$1.89M 1.67%
175
– –
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.85M 1.64%
3,111
– –
KURA icon
17
Kura Oncology
KURA
$800M
$1.72M 1.52%
633,692
-11,993
-2% -$37.3K
CARM
18
DELISTED
Carisma Therapeutics
CARM
$1.67M 1.48%
+50,000
New +$1.27M
ALDX icon
19
Aldeyra Therapeutics
ALDX
$92.9M
$1.66M 1.47%
291,230
+228,084
+361% +$1.27M
RIGL icon
20
Rigel Pharmaceuticals
RIGL
$681M
$1.56M 1.38%
+70,000
New +$1.74M
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.32M 1.17%
707
– –
NVET
22
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$720K 0.64%
154,840
– –
EPIX
23
DELISTED
ESSA Pharma
EPIX
$83K 0.07%
1,405
– –
ACHV icon
24
Achieve Life Sciences
ACHV
$659M
– –
-40
Closed -$60K
VTAE
25
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-315,025
Closed -$2.09M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Boxer Capital held 28 positions worth $113M, up 10% from $102M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Boxer Capital deployed $24.6M of net new capital in Q2 2016, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Acadia Healthcare: 200,938 shares worth $6.52M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $38K trimmed.

  • Boxer Capital's largest Q2 2016 buy was Acadia Healthcare: 200,938 shares worth $6.52M.
  • Boxer Capital added most to BeOne Medicines Ltd in Q2 2016, an estimated $2.25M increase.
  • Boxer Capital's biggest Q2 2016 reduction was Seagen Inc. Common Stock, cutting an estimated $38K.
  • Boxer Capital fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q2 2016, selling an estimated $9.21M.
  • Boxer Capital's ten largest holdings make up 74% of its $113M portfolio in Q2 2016.
  • Boxer Capital opened 6 new positions and closed 5 in Q2 2016.
  • Boxer Capital's portfolio value rose 10% quarter-over-quarter to $113M.

Based on Boxer Capital's 13F filing for Q2 2016, filed 15 Aug 2016.